ExpreS2ion enters multi-product agreement with US-based Integrated BioTherapeutics for expansion of their commercial reagents portfolio
Hørsholm, Denmark, July 17, 2017 – Today, ExpreS2ion Biotech Holding AB announces that the fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) has entered a Master Services Agreement and a Research & Commercial License Agreement with the US based Integrated BioTherapeutics, Inc. (“IBT”). The agreements enable standardised activation of a range of services and products from ExpreS2ion. This primarily targets the development and manufacturing of proteins based on the ExpreS2 platform, as well as granting IBT commercial rights to promote, sell and distribute such protein products made with ExpreS2. IBT expects to expand their unique research protein portfolio annually with up to five protein antigens manufactured in ExpreS2. ExpreS2ion and IBT do not disclose the financial terms of the agreements, which constitutes a part of both companies’ general business models, however, when the collaboration is fully implemented, ExpreS2ion expects to generate annual revenues of up to 1.0 million SEK as a result of these agreements.
Master Services Agreement (MSA) and Research & Commercial License Agreement (RCLA)
The MSA enables IBT to retain ExpreS2ion services and products for IBT research programs in a predefined and simple manner, according to the terms and conditions stipulated in the agreement. The agreement is made based on a common understanding by the parties that such services and products will be required. ExpreS2ion’s overall role will be development and manufacturing of selected protein antigens based on the efficient proprietary technology, ExpreS2.
The RCLA grants IBT the research and commercial rights to develop and market proteins made with the ExpreS2 technology. The RCLA contains an annual Research License Fee as well as Royalty of Net Sales to be paid by IBT to ExpreS2ion for such license grant. The Royalty of Net Sales is a two-digit percentage.
IBT expects to expand their unique research proteins franchise annually with up to five products developed with ExpreS2. ExpreS2ion and IBT do not disclose the financial terms of the Agreements, which constitutes a part of both companies’ general business models, however, when the collaboration is fully implemented, ExpreS2ion expects to generate annual revenues of up to 1.0 million SEK as a result of these agreements.
Integrated Biotherapeutics, Inc.
Integrated BioTherapeutics, Inc. (“IBT”) is a biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases. IBT's pipeline includes promising product candidates for bacterial and viral infections. IBT's antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines and a variety of other product candidates for emerging viruses, such as Zika, Ebola, dengue, Marburg, and others. IBT is located in Rockville, Maryland, USA, and has a close working relationship with United States Government agencies including the National Institute of Allergy and Infectious Diseases (NIAID/NIH), National Cancer Institute (NCI), United States Army Medical Research Institute of Infectious Diseases (USAMRIID), and many biotechnology and pharmaceutical companies and academic laboratories. IBT’s service and reagent division doing business as IBT Bioservices (www.ibtbioservices.com) produces and markets high quality recombinant proteins and antibodies primarily for infectious disease research.
CEO Dr. Steen Klysner comments
“I am pleased that we have established our first broad commercial agreement in reagent supply with IBT, which has direct sales and distribution to the market for high quality proteins used in research. This expands our near-term revenue business model and demonstrates the value of the ExpreS2 platform in this and related commercial segments. We look forward to this mutually beneficial collaboration with IBT and continued work in the future.”
Certified Adviser
Sedermera Fondkommission is appointed as Certified Adviser for ExpreS2ion.
For further information about ExpreS2ion Biotech Holding AB, please contact:
Dr. Steen Klysner, CEO
Telephone: +45 2062 9908
E-mail: sk@expres2ionbio.com
This press release contains information that ExpreS2ion is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above on July 17, 2017.
About ExpreS2ion
ExpreS2ion Biotechnologies ApS, is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique platform technology, ExpreS2, enabling cost effective development and robust production of complex proteins for new vaccines and diagnostics for e.g. Malaria and Zika. Since founded in 2010, the company has used its patented ExpreS2 platform to produce more than 200 proteins in collaborations with research institutions and biopharmaceutical companies, with a superior efficiency and success rate.
Tags: